Grifols SA (NAS:GRFS) Stock News, Headlines & Updates
Grifols SA Stock News from GuruFocus
- 1
- 2
- 3
Apr 19, 2024
Grifols 2023 Annual Report on Form 20-F filed with the SEC
PRNewswire • 4:00pm
Apr 18, 2024
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
Marketwired • 9:00am
Mar 28, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS
PRNewswire • 7:00pm
Mar 19, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS
PRNewswire • 6:00pm
Mar 12, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS
PRNewswire • 7:00pm
Feb 12, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS
PRNewswire • 2:08pm
Charles Brandes Adjusts Position in Grifols SA
GuruFocus Research • 6:03am
Charles Brandes Bolsters Position in Grifols SA
GuruFocus Research • 6:03am
Jan 23, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS
PRNewswire • 7:00pm
Jan 18, 2024
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF
PRNewswire • 5:00pm
Jan 14, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS
PRNewswire • 11:00am
Jan 12, 2024
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Grifols, S.A. (GRFS) on Behalf of Investors
Business Wire • 4:00pm
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Grifols, S.A. (GRFS) on Behalf of Investors
Business Wire • 12:00pm
Jan 11, 2024
GRFS SHAREHOLDER ALERT: Johnson Fistel Investigates Grifols, S.A. Following Short Seller Report
PRNewswire • 2:00pm
Jan 10, 2024
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF
PRNewswire • 3:00pm
Jan 09, 2024
ROSEN, A LEADING NATIONAL FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation -- GRFS, GIKLY, GIFOF, GIFLF
Business Wire • 11:00am
GRFS SHAREHOLDER ALERT: Johnson Fistel Investigates Grifols, S.A. Following Short Seller Report
Business Wire • 7:00am
Jan 02, 2024
What's Driving Grifols SA's Surprising 27% Stock Rally?
GuruFocus Research • 8:13am
Nov 06, 2023
GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023
Marketwired • 8:00am
Oct 19, 2023
GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins
Marketwired • 7:00am
Sep 28, 2023
GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564
Marketwired • 7:00am
Aug 01, 2023
Grifols Accelerates Healthcare Innovation with Google Cloud's AI and Analytics
Marketwired • 8:00am
Jul 20, 2023
Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients
Marketwired • 8:00am
Jul 18, 2023
Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis
Marketwired • 7:00am
Jul 13, 2023
Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency
Marketwired • 7:00am
Jun 18, 2022
GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development
GuruFocusNews • 11:11am
Jun 08, 2022
GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development
GuruFocusNews • 11:10am
May 29, 2022
GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development
GuruFocusNews • 11:10am
May 19, 2022
GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development
GuruFocusNews • 11:09am
Apr 14, 2022
David Herro Comments on Grifols
Sydnee Gatewood • 4:18pm
Aug 23, 2021
Grifols Sells Off With Effects of Pandemic
Holmes Osborne, CFA • 2:11pm
Jul 14, 2021
GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564
Marketwired • 9:00am
Jun 01, 2021
Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B
PRNewswire • 10:00am
May 19, 2021
Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona
PRNewswire • 5:00am
May 11, 2021
AzValor Comments on Grifols
Sydnee Gatewood • 5:04pm
AzValor Asset Management's 1st-Quarter Letter
Sydnee Gatewood • 4:50pm
Apr 28, 2021
Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the immune system and develop therapeutics
PRNewswire • 6:02am
Mar 09, 2021
Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins
PRNewswire • 3:00am
Mar 08, 2021
Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer's and Parkinson's Disease
Marketwired • 2:59pm
Grifols fosters world's first scientific journal specialized in blood plasma
PRNewswire • 7:02am
- 1
- 2
- 3
Show
Entries
Headlines
Total 0- 1
No recent news
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers